Market Overview

UPDATE: Stifel Nicolaus Initiates Covidien at Hold on Pending Spin-Off

Related COV
FDA Nod for Covidien's Kangaroo Feeding Tube - Analyst Blog
Edwards Lifesciences' Gain, Medtronic in Pain - Analyst Blog

Stifel Nicolaus initiated coverage on Covidien (NYSE: COV) with a Hold rating.

Stifel Nicolaus said, "In our view, there is very little one can find in the Covidien story that is not to like. Since the company's spin-off from Tyco five years ago, Covidien has set clear financial and operating goals and delivered on them with accelerating organic growth in its key business lines and significant gross margin expansion. Looking ahead, we think COV is poised for continued growth above its large-cap MedTech peers. However, a reasonable valuation and the potential for incremental pharma spin-off related dilution keep us on the sidelines."

Covidien closed at $56.17 on Monday.

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (COV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free